Relugolix

Category Pipeline APIs

Details	Specifications
CAS Number	737789-87-6
Molecular Formula	C29H27F2N7O5S
Molecular Weight	623.64 g/mol.
Synonyms	N-(4-(1-((2,6-Difluorophenyl) methyl)-5-((dimethylamino) methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d) pyrimidin-6-yl) phenyl)-N'-methoxy ureamethyl)-5-((dimethylamino)methyl)-1%2C2%2C3%2C4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2%2C4-dioxothieno(2%2C3-d)pyrimidin-6-yl)phenyl)-N%27-methoxyurea%22%5bCompleteSynonym%5d%20AND%2010348973%5bStandardizedCID%5d)
Chemical Name	1-[4-[1-[(2,6-difluorophenyl) methyl]-5-[(dimethylamino) methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d] pyrimidin-6-yl] phenyl]-3-methoxyurea
Therapeutic use	Relugolix is indicated for the treatment of adult patients with advanced prostate cancer. In a combination product with estradiol and norethindrone, relugolix is indicated for the once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Status	Tech pack available
Background	Relugolix was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer. This branded product was later approved by the European Commission on April 29, 2022.
Grade	In-house
Polymorph	Form I
Storage Temperature	Controlled room temperature (20?C ? 25?C)

Please Note: We partner exclusively with pharmaceutical manufacturers, biotech companies, and international trading firms. Minimum order quantities apply*

Disclaimer:

The information provided on this webpage is based on the best available knowledge at the time of publication; however, accuracy and completeness are not guaranteed. Product specifications may change without notice. It is the responsibility of the purchaser or user to verify suitability and compliance. This product is intended for research use only and is not approved for human consumption.

Why Shilpa Pharma?

Happy Customers

Projects Successfully Completed

Established

PhD Experts Driving R&D Excellence

Team Size

World-Class API Manufacturing Sites

Global Audits Successfully Completed

Comprehensive CDMO Service Offerings

Our Relugolix are also Available for

Questions & Answers

FAQ on Relugolix

Everything You Need to Know About Shilpa Pharma

Shilpa Pharma – Your Trusted Global CDMO Partner

Delivering end-to-end solutions across API oncology, generics, peptides, polymers and specialty chemicals, we empower partners to accelerate development, ensure compliance, and reach markets faster with reliable, cost-effective innovation.